Metrion Biosciences has appointed John Montana as a Non-Executive Director. Expansion of the board of directors is aimed to support the company’s further growth.
Dr Montana brings more than 30 years’ drug discovery and development experience across the pharmaceutical, biotech, and contract research sectors. He’s currently Operating Partner at Forbion, the life science venture capital firm, and previous roles have included Corporate VP, Integrated Drug Discovery, at Charles River Labs, as well as multiple C-suite positions such as CSO at Argenta, CEO of Amedis, Head of Chemistry at Chiroscience, along with various roles at GlaxoSmithKline. He holds a BSc in Chemistry from The University of Manchester and a PhD in Medicinal Chemistry from the University of East Anglia.
Dr Keith McCullagh, Chairman of Metrion Biosciences, said: “I am pleased to welcome John Montana to Metrion Biosciences’ board of directors. John brings substantial experience of building effective scientific CRO operations as well as a successful track record in drug discovery. He will be an asset to Metrion’s Board and contribute significantly to the Company’s further growth and international development.”
Montana commented: “I am delighted to be joining Metrion at such an exciting time for the Company. Metrion has established itself as a leader in the ion channel contract research and drug discovery space and I look forward to joining the team and the Board on this journey, working together to extend Metrion’s capabilities.”
